Chris D. Alafi
Founder at Alafi Capital Co. LLC
Net worth: 57 M $ as of 31/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Sharon Mates | M | 71 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 22 years |
Michael Rawlins | M | 82 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 2 years |
Lawrence Hineline | M | 67 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 22 years |
Rory Riggs | M | 71 |
ITI, Inc. (New York)
Nuredis, Inc.
Nuredis, Inc. BiotechnologyHealth Technology Nuredis, Inc. develops treatments for neurodegenerative and neuromuscular diseases. The private company is based in Menlo Park, CA. The company was founded by Stanley N. Cohen. | 10 years |
Kimberly E. Vanover | M | 58 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 7 years |
Allen A. Fienberg | M | 64 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 12 years |
Kimberly Peery | F | 55 | 21 years | |
Michael Halstead | M | 51 |
ITI, Inc. (New York)
| 10 years |
Joel Marcus | M | 76 |
ITI, Inc. (New York)
| 18 years |
Lawrence P. Wennogle | M | 74 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 17 years |
Robert van Nostrand | M | 67 |
ITI, Inc. (New York)
| 10 years |
David Benfer | M | 77 | 19 years | |
Juan F. Sanchez | M | - | 10 years | |
Robert Messey | M | 78 | 19 years | |
Mark Neumann | M | 61 | 6 years | |
Michael S. Tropea | M | - | 14 years | |
Robert Davis | M | 73 | 9 years | |
Karen Sheehy | F | 62 | 5 years | |
Suresh Durgam | M | 55 | 6 years | |
Michael Olchaskey | M | - | 6 years | |
John A. Bardi | M | - | 5 years | |
Stanley Cohen | M | - |
Nuredis, Inc.
Nuredis, Inc. BiotechnologyHealth Technology Nuredis, Inc. develops treatments for neurodegenerative and neuromuscular diseases. The private company is based in Menlo Park, CA. The company was founded by Stanley N. Cohen. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Samir Naji Masri | M | 79 | - | |
Richard Alan Lerner | M | 85 |
Intra-Cellular Therapies, Inc. /Old/
Intra-Cellular Therapies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company's technology addresses diseases of the central nervous system, including schizophrenia, cognition, Parkinson's disease, anxiety, depression, Alzheimer's disease, sleep, and those related to women's health. Its products include clinical development plan for schizophrenia and unique mechanism of action. Intra-Cellular Therapies was founded by Paul Greengard, Sharon Mates and Allen A. Fienberg on May 22, 2001 and is headquartered in New York, NY.
ITI, Inc. (New York)
| 19 years |
Martin C. Stammer | M | 43 | 10 years | |
Samuel W. Duggan | M | 60 | 2 years | |
Moshe H. Alafi | M | - |
Alafi Capital Co. LLC
Alafi Capital Co. LLC Investment ManagersFinance Alafi Capital Co. LLC (Alafi Capital) is a venture capital firm founded by Christopher alafi in 1995. The firm is headquartered in San Francisco, California. | 28 years |
Douglas Michael Bruce | M | 66 | 11 years | |
Michael Kaminski | M | 63 | 11 years | |
William M. Kelley | M | 88 | - | |
Pierre Rivaux | M | - | - | |
James Stolze | M | 81 | 5 years | |
Peggy S. Stohr | F | 59 | 10 years | |
Patricia Kennedy | F | 63 | 7 years | |
Eric N. Prystowsky | M | 76 | - | |
Karen Witte Duros | F | 69 | - | |
Frank J. Cheng | M | 56 | 6 years | |
Melissa C. Walker | F | 67 | - | |
Ashish Dugar | M | - | 2 years | |
Gery Tomassoni | M | - | - | |
Peter Takes | M | - | 14 years | |
Paul Greengard | M | - | - | |
Cedric O'Gorman | M | 49 | 3 years | |
Paul A. Brathwaite | M | - | - | |
David Jacques | M | 61 | 6 years | |
Chaucer Shen | M | - | 3 years | |
Andrew Satlin | M | 69 | 3 years | |
Ralph G. Dacey | M | 75 | 6 years | |
James L. Nouss | M | - | - | |
Daniel J. Johnston | M | 66 | 2 years | |
Terry R. Colvin | M | 68 | 1 years | |
Bevil J. Hogg | M | 76 | 13 years | |
John C. Aplin | M | 78 | - | |
Greg R. Johnson | M | 80 | 14 years | |
Abhijeet Lele | M | 58 | 6 years | |
Joseph Keegan | M | 71 | 5 years | |
David A. Giffin | M | 75 | - | |
Kevin T. Shifrin | M | 58 | - | |
Kelly W. Elliott | F | 62 | 1 years | |
Ruchir Sehra | M | 55 | 2 years | |
Louis Ruggiero | M | 64 | 1 years | |
Abhi Acharya | M | 83 | 3 years | |
Douglas T. Kurschinski | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 63 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Chris D. Alafi
- Personal Network